Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and currently trading at $795.67. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO) and whether or not the dip is worth buying over Eli Lilly (NYSE: LLY). Watch the short video to learn more, consider subscribing,